Last reviewed · How we verify
Adverse Reactions of Gammagard subcutaneously at Week 12
Adverse Reactions of Gammagard subcutaneously at Week 12 is a Small molecule drug developed by ASIS Corporation. It is currently in Phase 1 development. Also known as: Gammagard [Immune Globulin Infusion (Human)].
At a glance
| Generic name | Adverse Reactions of Gammagard subcutaneously at Week 12 |
|---|---|
| Also known as | Gammagard [Immune Globulin Infusion (Human)] |
| Sponsor | ASIS Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ASIS for GAMMAGARD in Primary Immunodeficiency (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adverse Reactions of Gammagard subcutaneously at Week 12 CI brief — competitive landscape report
- Adverse Reactions of Gammagard subcutaneously at Week 12 updates RSS · CI watch RSS
- ASIS Corporation portfolio CI
Frequently asked questions about Adverse Reactions of Gammagard subcutaneously at Week 12
What is Adverse Reactions of Gammagard subcutaneously at Week 12?
Adverse Reactions of Gammagard subcutaneously at Week 12 is a Small molecule drug developed by ASIS Corporation.
Who makes Adverse Reactions of Gammagard subcutaneously at Week 12?
Adverse Reactions of Gammagard subcutaneously at Week 12 is developed by ASIS Corporation (see full ASIS Corporation pipeline at /company/asis-corporation).
Is Adverse Reactions of Gammagard subcutaneously at Week 12 also known as anything else?
Adverse Reactions of Gammagard subcutaneously at Week 12 is also known as Gammagard [Immune Globulin Infusion (Human)].
What development phase is Adverse Reactions of Gammagard subcutaneously at Week 12 in?
Adverse Reactions of Gammagard subcutaneously at Week 12 is in Phase 1.
Related
- Manufacturer: ASIS Corporation — full pipeline
- Also known as: Gammagard [Immune Globulin Infusion (Human)]
- Compare: Adverse Reactions of Gammagard subcutaneously at Week 12 vs similar drugs
- Pricing: Adverse Reactions of Gammagard subcutaneously at Week 12 cost, discount & access